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Abstract
Background and Objective Omeprazole is a proton pump inhibitor (PPI) that is used in acid suppression therapy in infants. 
In this study we aimed to develop a pediatric omeprazole suppository, with good physical and chemical stability, suitable 
for pharmaceutical batch production.
Methods The composition of the suppository consisted of omeprazole, witepsol H15 and arginine (L) base. To achieve 
evenly distributed omeprazole suspension suppositories, the temperature, stirring rate, and arginine (L) base amount were 
varied. A previously validated quantitative high-performance liquid chromatography–ultraviolet method was modified and 
a long-term stability study was performed for one year.
Results Evenly distributed omeprazole suspension suppositories were obtained by adding 100 mg arginine (L) base and 
pouring at a temperature of 34.7 °C and a stirring speed of 200 rpm. The long-term stability study showed no signs of dis-
coloration and a stable omeprazole content between 90 and 110% over 1 year if stored in the dark at room temperature.
Conclusion We developed a pediatric omeprazole suppository. This formulation may provide a good alternative to manipu-
lated commercial or extemporaneously compounded omeprazole oral formulations for infants. Clinical studies are needed 
to establish efficacy and safety in this young population.
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Key Points 
We report the development of a pediatric omeprazole 
suppository, by adding witepsol and 100 mg arginine (L) 
base and pouring at a temperature of 34.7 °C and a stir-
ring speed of 200 rpm.
The one-year stability study found that the suppositories 
showed no signs of discoloration and that the omepra-
zole content remained stable between 90 and 110% if 
stored in the dark at room temperature.
1 Introduction
Omeprazole (5-methoxy-2-[(RS)-[(4-methoxy-3,5-dimeth-
ylpyridin-2-yl)methyl]sulfinyl]-1H-benzimidazole), a proton 
pump inhibitor (PPI), inhibits gastric acid secretion by inac-
tivating the H +/K + ATPase molecules of the parietal cell in 
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the stomach mucosa selectively and non-competitively [1]. 
This effect on the final step of gastric acid formation is dose-
dependent and inhibits both basal and stimulated gastric acid 
secretion. Omeprazole is a lipophilic weak base that decom-
poses in an acidic environment. To prevent decomposition 
in the acid environment of the stomach, an enteric coating 
is used in most oral formulations [1]. This coating is soluble 
in the alkaline environment of the small intestine and ome-
prazole is rapidly absorbed in the small intestine and passes 
into the bloodstream. Peak plasma concentrations occur in 
adults within 3–6 h and the bioavailability is around 60% 
after repeated dosing. The plasma half-life of omeprazole is 
approximately 1 h; however, the anti-secretory effect lasts 
for a more prolonged time due to irreversible binding to 
H +/K + ATPase molecules of the parietal cell.
PPIs are used in acid suppression therapy in infants with 
gastroesophageal reflux disease (GERD) [2]. GERD often 
occurs in infants with congenital anomalies, such as esopha-
geal atresia (EA) or congenital diaphragmatic hernia (CDH) 
[3–5]. In contrast to adults, however, no commercially regis-
tered oral dosage form of omeprazole is available for infants 
younger than 1 year of age. Due to their small size, infants 
require a non-standard dose. Based on a small number of 
pharmacokinetic and clinical studies in infants, the start-
ing dose is 1 mg/kg/day, which can be increased in steps of 
0.5 mg/kg/day to a maximum of 3 mg/kg/day [6, 7]. Addi-
tionally, infants are unable to swallow oral tablets or cap-
sules. In clinical practice, omeprazole is often administered 
as extemporaneous formulations by crushing the omeprazole 
microgranules, which may destroy the enteric coating, or by 
suspending the microgranules in water or sodium bicarbo-
nate [8]. The amount of sodium bicarbonate needed to safely 
alkalize the gastric acid is not known for infants. When ome-
prazole tablets or capsules are dissolved in water or juice, 
infants may chew on the microgranules causing damage to 
the enteric coating. Consequently, the oral bioavailability 
of these extemporaneous omeprazole administrations may 
be unpredictable and may result in variable degrees of drug 
exposure although this has not been studied in the pediat-
ric population [9]. This may also explain the reported low 
effectiveness of omeprazole in infants with GERD [7]. In 
particular, for infants who need nasogastric tube feeding, 
omeprazole administration via a gastric tube often results 
in omeprazole deposits and tube occlusion. The replace-
ment of the nasogastric tube is a very stressful experience 
for the infants and their parents. It is clear that the current 
oral administration of omeprazole in infants results in unpre-
dictable exposure levels and added burden for patients and 
parents. This reduces the drug compliance and does not con-
tribute to a good clinical effect.
To increase the effectiveness of omeprazole therapy in 
infants, rectal administration may potentially overcome 
the limitations associated with oral omeprazole. Moreover, 
when young infants reject oral formulations, suppositories 
present a more secure way of drug administration. In 1969, 
Kerawalla et al. compared oral versus rectal indomethacin 
suppositories in young infants and found them to be well 
tolerated, convenient to administer, and showed no local 
side-effects [10]. A frequently prescribed drug for which 
suppositories are widely used as an alternative for oral for-
mulations is acetaminophen [11, 12]. In addition, omepra-
zole as a suppository appears to be an effective dosage form 
in healthy adults, resulting in adequate systemic exposure 
and acid reduction [13, 14]. Hence, the aim of this study was 
to develop a pediatric omeprazole suppository suitable for 
infants with GERD, including adequate stability and suit-
ability for pharmaceutical batch production.
2  Methods
The raw material, i.e., omeprazole and the pharmaceutical 
excipients, namely arginine (L) base and witepsol H15 were 
purchased from BUFA (BUFA, IJsselstein, The Netherlands) 
and were of European Pharmacopeia grade. BUFA is one 
of the suppliers designated by the NVZA (Dutch Associa-
tion of Hospital Pharmacists). Omeprazole and the phar-
maceutical excipients were processed by BUFA according 
to Pharmacopeia European Monograph and delivered with 
the corresponding certificate of analysis. Upon arrival of 
the materials in the hospital pharmacy (Rijnstate Hospital, 
Arnhem), an entry check was carried out in accordance with 
the analytical certificate. All other chemicals and solvents 
were of analytical reagent grade.
2.1  Composition
As a starting point for the design of the suppository, ome-
prazole, arginine (L) base, and witepsol H15 were included 
[13]. The dosage strengths of the omeprazole suppositories 
were chosen based on the oral omeprazole starting dose of 
1 mg/kg and were aimed at the 6 weeks to 1 year age range. 
Omeprazole suppositories were produced in 8 different 
strengths (3 mg through 10 mg). The suppositories were 
produced with the suppository molding unit from Erweka 
(Gemini BV, Apeldoorn, The Netherlands). For omeprazole 
and arginine (L) base, a displacement factor of 0.65 was 
used. The used suppository molds were transparent and had 
a capacity of 1.15 ml. In order to achieve an evenly distrib-
uted omeprazole suspension suppository, the following fac-
tors were varied to obtain an optimal preparation process—
temperature, stirring rate, and arginine (L) base amount per 
suppository (10 mg vs 100 mg), as described in more detail 
below.
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2.2  Temperature and Stirring Speed
To optimize the suppository consistency and omeprazole 
distribution, the temperature of the suppository mass was 
varied in the range of 32–37 °C and the stirring speed was 
varied between 150 and 350 rpm. The consistency of the 
mass was determined by the uniformity of mass (European 
Pharmacopeia 9.0 Monograph, omeprazole). Physical analy-
sis also included visual examination—shape, surface, color 
and texture. Distribution of omeprazole across the supposi-
tory was first determined in petroleum ether by visual exami-
nation. In addition, the suppository was sectioned laterally 
ensuring that each section (the point and tail of the sup-
pository) quantitatively (Sect. 2.4) contained proportionally 
equal amounts of omeprazole.
2.3  Arginine (L) Base Amount per Suppository: 
10 mg Versus 100 mg
Arginine (L) base was added to the omeprazole supposi-
tory to minimize degradation of the suppository during the 
storage period. Two different amounts of arginine (L) base 
(10 mg and 100 mg per suppository) were tested to investi-
gate whether or not arginine (L) base affects the solidifica-
tion time and omeprazole distribution over the suppository; 
arginine base (L) does not dissolve in the suppository base 
witepsol and as a result sedimentation and migration of the 
arginine (L) base to the bottom of the suppository can occur. 
The effects on the solidification time and the distribution of 
omeprazole and arginine (L) base over the suppository were 
determined.
2.4  Analytical Method
For the quantitative analysis of omeprazole and related 
compound (European Pharmacopeia 9.0 Monograph ome-
prazole) D [5-methoxy-2-[[(4-methoxy-3,5-dimethylpyri-
din-2-yl)methyl]sulfonyl]-1H-benzimidazole(omeprazole 
sulphone), a high-performance liquid chromatography 
combined with ultraviolet (HPLC–UV) method was used, 
modified from the European Pharmacopeia 9.0 Monograph 
of omeprazole.
This method was modified because omeprazole, the deg-
radation products (including omeprazole sulphone) and the 
internal standard lansoprazole had to be separately detect-
able. By modifying the method, good chromatograms with 
sharp, separated peaks were obtained in a single run. Meas-
urements were also taken at 302 nm instead of 280 nm.
Omeprazole was removed from the suppository by extrac-
tion, since omeprazole is very slightly soluble in water. The 
suppository was placed in an Erlenmeyer flask and 25 ml of 
dichloromethane, 10 ml of internal standard lansoprazole 
solution (3 mg/l) and 15 ml of 0.1 mol/l sodium hydroxide 
were added. The Erlenmeyer flask was shaken vigorously for 
1 min after which 250 µl of the top layer was pipetted into 
a 10 ml volumetric flask and supplemented with the eluent. 
Omeprazole, lansoprazole and omeprazole sulphone were 
separated using a Shimadzu LC20 system on a C18 analyti-
cal column (Inertsil ODS-5) with a mixture of acetonitrile 
R (standardized pharmacopoeia solution) and a solution of 
1.4 g/L disodium hydrogen phosphate R, adjusted to the 
right pH with phosphoric acid R (standardized pharmaco-
poeia solution) as a mobile phase at a flow rate of 1 ml/min. 
UV detection for quantification was kept at a wavelength of 
302 nm. The injection volume was 25 µl.
The composition of the eluent (proportion of phosphate 
buffer/acetonitrile), the pH, and the column temperature were 
varied to achieve an optimal analytical method; peaks had to 
be well separated and should not tail. Lansoprazole was cho-
sen as the internal standard for the omeprazole HPLC method 
since lansoprazole is also a PPI and behaves chemically in the 
same way as omeprazole, with no overlap in the chromato-
gram with omeprazole or omeprazole-sulphone. The method 
was validated for the quantification of omeprazole in the sam-
ple matrix witepsol H15 and in the presence of omeprazole 
sulphone. The validation parameters are shown in Table 1.
2.5  Long‑Term Stability Study
The influence of light and temperature on the long-term stabil-
ity of the omeprazole suppositories was investigated. For this 
study, the definitive composition of the omeprazole supposito-
ries was used, which consisted of witepsol H15, omeprazole, 
and 100 mg arginine (L) base. Omeprazole suppositories with 
the lowest strength of 3 mg (A) and with the highest strength 
of 10 mg (B) were studied over one year. The samples were 
stored under the following conditions, namely:
(1) in a climate cabinet at 4 °C (range 2–8 °C)
(2) in the dark at room temperature (< 25 °C)
(3) in daylight at room temperature (< 25 °C).
The temperature of the climate cabinet was monitored 
and registered. The samples were analyzed at 0, 1, 2, 3, 4, 5, 
6, 9 and 12 months using the modified stability-indicating 
HPLC–UV method for determination of omeprazole and 
omeprazole sulphone. End-of-shelf-life specifications are 
based on the European Pharmacopeia 9.0 Monograph for 
omeprazole—the suppositories must not be colored and the 
omeprazole content must be between 90 and 110%.
2.6  Manufacturing Procedure
The manufacturing procedure was developed for batch com-
pounding. The arginine (L) base was first rubbed finely into 
a rough stone mortar followed by omeprazole mixed in equal 
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parts with the arginine (L) base. Witepsol H15 was melted in 
a stainless steel mortar on a water bath of 50–60 °C, while 
stirring continuously, after removing from the water bath 
before the mass had completely melted, and the temperature 
was measured (40–45 °C). Next, the omeprazole–arginine 
(L) base mixture was mixed with equal parts of witepsol 
H15, followed by the remaining witepsol H15. At a tem-
perature of 35–35.5 °C, the suppository mass was transferred 
to the suppository molding machine and poured in suitable 
rectal forms.
2.7  Statistical Analysis
We calculated the recovery and coefficient of variation (CV) 
as the mean of 6 different samples analyzed by one labora-
tory technician. For the inter-assay CV, the values of three 
technicians were used. All of these values were compared 
with standard specifications as listed in Table 1. For linear-
ity, the lack-of-fit and goodness-of-fit were assessed using 
four concentrations in the range of 1–15 mg/L measured in 
triplicate and compared with the F value for the relevant 
degrees of freedom and a p value of 0.05. SPSS Statistics, 
version 26.0 (IBM Corp, New York, USA) was used for 
statistical analysis.
3  Results
3.1  Composition
Based on the data regarding the temperature, the stirring 
speed, and the amount of arginine (L) base (as described 
below in more detail), 100 mg of arginine (L) base was 
added per suppository, and the suppositories were poured 
at a temperature of 34.7 °C, and a stirring speed of 200 rpm 
was used. The composition of a 4-mg omeprazole supposi-
tory consists of 4 mg omeprazole, 100 mg arginine (L) base 
and 1,002 g witepsol H 15. The batch size was 600 supposi-
tories at a time.
3.2  Temperature and Stirring Speed
A pouring temperature > 35 °C and a stirring speed < 180 
rpm resulted in the sedimentation and migration of the ome-
prazole and the arginine (L) base to the bottom of the sup-
pository. A pouring temperature < 34.5 °C and a stirring 
speed of > 250 rpm resulted in suppositories that were too 
light and too brittle. Optimal omeprazole suppositories were 
obtained when poured at a temperature of 34.7 °C and a 
stirring speed of 200 rpm. The suppositories were torpedo 
shaped, white colored and homogeneous with no cracks/air 
bubbles/bursts, and the inside and outside of the suppository 
had a smooth uniform surface. The suppositories met the 
requirements of the uniformity of mass. Each section of the 
suppository (point and tail) contained proportionally equal 
amounts of omeprazole.
3.3  The Arginine (L) Base Amount per Suppository: 
10 mg Versus 100 mg
Adding 100 mg of arginine (L) base to the suppository 
resulted in a good omeprazole distribution across the sup-
pository (point and tail analysis). The arginine (L) base 
amount (10 mg or 100 mg) did not affect the solidification 
Table 1  Validation parameters of the modified HPLC–UV analytical method
HPLC–UV high-performance liquid chromatography combined with ultraviolet, LLOQ lower limit of quantification, LOD limit of detection, 
LOF lack-of-fit
Parameter Test n Specification Result
Accuracy (3 µg/ml) Recovery (%) 6 98–102 98.8
Coefficient of variation (%) 6 < 1 0.5
Accuracy (10 µg/ml) Recovery (%) 6 98–102 100.2
Coefficient of variation (%) 6 <1 0.4
Linearity (0–15 µg/ml) LOF [F value (8;1 p = 0.05)] 12 < 5.32 1.45
Correlation coefficient 12 > 0.995 0.997
Limits LOD (µg/ml) 12 – 0.85
LLOQ (µg/ml) 12 – 1.81
Intra-assay precision (3 µg/ml) Coefficient of variation (%) 6 < 1 0.49
Intra-assay precision (10 µg/ml) Coefficient of variation (%) 6 < 1 0.39
Inter-assay precision (3 µg/ml) Coefficient of variation (%) 6 < 2 0.98
Inter-assay precision (10 µg/ml) Coefficient of variation (%) 6 < 2 1.58
Specificity Omeprazole (%) 2 > 99.5 99.7
Related compound D (%) 2 > 99.5 99.6
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time and the distribution. Arginine (L) base was added to 
the suppository to prevent degradation; this pharmaceutical 
excipient is not absorbed by the intestine and can therefore 
be used safely in children. If a suppository contains < 50 mg 
of pharmacon then 100 mg of filler should be added. Since a 
good suppository was obtained with both 10 mg and 100 mg 
arginine (L) base, the decision was made to add 100 mg argi-
nine (L) base, because the arginine (L) base can also be used 
as a filler to supplement the amount of solids to > 100 mg, 
obviating the need of other fillers.
3.4  Analytical Method
A previously reported HPLC–UV method was modified 
and validated. Omeprazole, lansoprazole and omeprazole 
sulphone were separated on a C18 analytical column with 
a mixture of acetonitrile R and a solution of 1.4 g/L diso-
dium hydrogen phosphate R, adjusted to pH 6.5 with phos-
phoric acid R (72.5: 27.5) as a mobile phase at a flow rate 
of 1 ml/min. With changes in the composition of the eluent 
(proportion of phosphate buffer 70–75/acetonitrile 25–30) 
and the pH 6.5–8.5, the retention time, the peak shape, and 
the separation changed. This mobile phase displayed well-
separated sharp peaks and no tailing. The retention times 
were omeprazole 3.3 min, omeprazole sulphone 4.5 min, and 
lansoprazole 7.5 min. The column temperature was optimal 
at 25°C. Increasing the column temperature deteriorated 
the shape of the peaks. UV detection for quantification was 
kept at a wavelength of 302 nm. The injection volume was 
25 µl. The validation parameters of the HPLC–UV method 
developed are shown in Table 1. The most effective mobile 
phase obtained consisted of a mixture of acetonitrile R and a 
solution of 1.4 g/L disodium hydrogen phosphate R adjusted 
to pH 6.5 with phosphoric acid R.
3.5  Specificity
The influence of the matrix (witepsol H15 and arginine (L) 
base) on the chromatogram was determined by preparing a 
test formulation without the active substance and handling 
this test formulation in the same way as a test formulation 
with omeprazole. No disturbing peaks of the matrix were 
present in the chromatogram. For further validation, arginine 
(L) base was not included, since it does not dissolve and 
remains on the bottom of the Erlenmeyer flask.
3.6  Recovery
The recovery of the components to be determined in the 
matrix was investigated using the test mixture method. The 
recovery was determined by making two 8-point calibra-
tion lines. One calibration curve included the matrix and 
extraction and the other calibration line was made without 
matrix and extraction. The comparison of the calibration 
lines showed that the extraction procedure had no influence 
on the recovery, since the two lines differed little from each 
other in terms of correlation and slope. Therefore, the deci-
sion was made to continue to use the calibration curve with 
matrix and extraction in the study as it mimics the composi-
tion and the work-up of the omeprazole suppository.
3.7  Long‑Term Stability Study
After storage of the suppositories for 1 year under condi-
tions 1 [in a climate cabinet at 4 °C (range 2–8 °C)] and 
2 [in the dark at room temperature (< 25 °C)], the color, 
weight and content (within 90–110% range) remained sta-
ble (Fig. 1). After storage under condition 3 for 1 year [in 
daylight at room temperature (< 25 °C)], the suppositories 
were discolored to yellow and the content had fallen sharply 
(± 85% of the declared value of the omeprazole 10 mg sup-
positories and ± 70% of the declared value of the omeprazole 
3 mg suppositories). On the basis of the shelf life test, the 
suppositories need to be kept at room temperature in the 
Fig. 1  Average omeprazole concentration over time for omeprazole 
3  mg (a) and omeprazole 10  mg (b) suppositories under different 
storage conditions
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dark to guarantee a shelf life of 1 year for all strengths of the 
omeprazole suppositories tested.
4  Discussion
In this study, we developed omeprazole suppositories of 
3–10 mg with good physical and chemical stability, which 
are suitable for use in infants. The manufacturing process 
was optimized and is suitable for preparing small or large 
batches. The long-term stability study showed a shelf life of 
1 year provided the suppositories are stored in the dark at 
room temperature.
As the basis for this omeprazole suppository, the same phar-
maceutical excipients as in the study by Choi et al. [13] were 
used. Witepsol H15 is used frequently as a suppository base in 
many infant suppositories and can be used safely. Arginine (L) 
base is added to the suppository to minimize degradation of 
the omeprazole suppository; this pharmaceutical excipient is 
not absorbed by the intestine and can therefore be used safely 
in children. Choi et al. used 1% arginine (L) base (w/w) per 
suppository and did not investigate different amounts of argi-
nine (L) base. In our study, we examined whether the amount 
of arginine (L) base (10 mg or 100 mg) affected the quality 
of the suppositories. Arginine base (L) does not dissolve in 
the suppository base witepsol and, as a result, sedimentation 
and migration of the arginine (L) base to the bottom of the 
suppository can occur. However, in the study by Choi et al., 
the preparation process is described very briefly, with only the 
temperature during mixing being mentioned. The stirring speed 
and the pouring temperature were not investigated, but are of 
great importance for preparing a good suppository. We tested 
two different amounts of arginine (L) base (10 mg and 100 mg) 
per suppository.
With both quantities (10 mg and 100 mg), an evenly 
distributed suppository was obtained. By adding 100 mg 
arginine (L), we obviated the need to use an additional 
filler. This is especially relevant in infants, where toxicity 
of excipients may present as a higher risk than in adults. For 
a good clinical result, omeprazole suppositories have to be 
prepared with a good distribution of omeprazole across the 
suppository.
The biggest challenge in the development of the ome-
prazole suppository was to prevent the sedimentation and 
migration of the omeprazole and arginine (L) base to the tip 
of the suppository. In a suspension suppository, the phar-
maceutical particles may settle down as long as the base 
has not yet solidified. The omeprazole suppository must be 
poured at the lowest possible temperature and, once poured, 
it must be solidified immediately to prevent the omepra-
zole from settling down in the tip of the suppository, which 
partly remains in the strip. The stirring speed was also 
of great importance. A too low stirring speed resulted in 
omeprazole suppositories which showed settlement in the 
tip and a too high stirring speed resulted in omeprazole sup-
positories which were too brittle and too light due to too 
much air being impacted. Optimal omeprazole suspension 
suppositories were obtained with 100 mg arginine (L) base, 
pouring at a temperature of 34.7 °C and a stirring speed 
of 200 rpm. For quantitative analysis of omeprazole, the 
internal standard and omeprazole sulphone, a previously 
developed HPLC–UV method was modified and validated. 
The composition of the eluent, the pH of the eluent and the 
column temperature were optimized to obtain the most suit-
able analytical method.
Another challenge was to quantify omeprazole in the 
omeprazole suppositories, since omeprazole is only very 
slightly soluble in water. An extraction method was devel-
oped to separate omeprazole from the witepsol H15. The 
suppository was placed in a mixture of dichloromethane, 
internal standard and 0.1 mol/l of sodium hydroxide and, 
after shaking for one minute, the omeprazole, omeprazole-
sulphone (if present) and internal standard were separated 
from the witepsol and were located in the upper layer of the 
mixture. A small amount of this layer was further processed 
to be injected on the HPLC–UV. To obtain suppositories 
with a good shelf-life, storage in the dark at room tempera-
ture was important to prevent the suppositories from dis-
coloring and to ascertain stable omeprazole concentrations.
4.1  Limitations
The omeprazole suppositories were successfully formulated 
at laboratory scale; however, to scale-up to commercial 
production, more research is necessary. Scaling up requires 
other pieces of equipment, the suppository mass is larger and 
the suppositories are often cooled after pouring into molds. 
As a result, the pouring temperature and the stirring speed 
can be different when scaling up, and research is necessary 
into the relationship between melting and solidification time. 
All of these factors are extremely critical for the physical and 
chemical properties of the final suppositories.
In this study we do not have clinical data to provide infor-
mation about the effectiveness and the pharmacokinetic 
parameters. This information is provided in an accompany-
ing article [15]. We have not conducted research on paren-
tal acceptance and preference for suppositories versus oral 
medications, so we cannot make any assumptions about their 
use in the clinic.
5  Conclusion
We developed and validated a pediatric omeprazole supposi-
tory suitable for infants with GERD. To study the efficacy 
and pharmacokinetics of this newly developed omeprazole 
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suppository in infants with GERD due to EA or CDH we 
conducted a randomized controlled trial [15]. In this trial, 
we compared rectally administered with orally administered 
omeprazole and found a consistent increase in intraesoph-
ageal and gastric pH in infants with EA- or CDH-related 
GERD, similar to an oral dose. Since the manufacturing 
process is suitable for batch compounding we conclude that 
rectal omeprazole presents as an innovative, promising alter-
native for infants with pathological GERD.
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